ATA Guidelines Tools

Thyroid Disease in Preconception, Pregnancy, and Postpartum

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1545288

Contents of this Issue

Navigation

Page 31 of 53

Hyperthyroidism 32 Recommendations Table 15. Subclinical and Overt Hyperthyroidism in Pregnancy Strength * Level # Subclinical hyperthyroidism or GTT should not be treated with ATD therapy, but propranolol may be used to ameliorate hyperthyroidism-related palpitations. Strong Moderate In pregnant women with subclinical hyperthyroidism whose TSH concentration is <0.1 mU/L, serum thyroid function should be monitored without treatment every 2–4 weeks. Good Practice Statement Overt hyperthyroidism that is not due to GTT (i.e., Graves' disease, autonomous thyroid nodule) should be treated, to minimize the duration of uncontrolled thyrotoxicosis in pregnancy. Good Practice Statement Overt hyperthyroidism not due to GTT (i.e., Graves' disease, autonomous thyroid nodule) may be treated with ATD therapy, targeting a FT4 concentration at or slightly above the upper third of the reference interval. a Conditional Moderate a Because FT4 concentrations below this range are associated with a high risk of fetal hypothyroidism. * Strength of Recommendation; # Level of Evidence; Good Practice Statement.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Thyroid Disease in Preconception, Pregnancy, and Postpartum